Join to view full profile
9500 Euclid AveCleveland, OH 44195
Phone+1 216-445-9365
Dr. Hassan is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Khaled Hassan is an oncologist in Cleveland, OH and is affiliated with multiple hospitals in the area, including Michigan Medicine, Veterans Affairs Ann Arbor Healthcare System, and Cleveland Clinic. He received his medical degree from Kursk State Medical University and has been in practice 19 years. He specializes in hematologic oncology and thoracic cancer and is experienced in thoracic oncology.
Education & Training
University of MichiganFellowship, Hematology and Medical Oncology, 2006 - 2009
Good Samaritan Hospital of MarylandResidency, Internal Medicine, 2003 - 2006
Kursk State Medical UniversityClass of 1998
Certifications & Licensure
OH State Medical License 2014 - 2028
MI State Medical License 2007 - 2020
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification OpTime Surgical 2014 Certified Module, Epic Systems Corporation, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification Beacon Oncology 2014 Certified Module, Epic Systems Corporation, 2013-2014, 2016-2017
- CMS Meaningful Use Stage 2 Certification Outgoing Public Health Reporting from EpicCare Functionality, Epic Systems Corporation, 2013-2014, 2016-2017
Publications & Presentations
PubMed
- Immune Checkpoint Inhibitor-Associated Uveitis: Insights From Comparative Analyses Across Malignancies and Drug Classes.Victor Bellanda, Matthew J Schulgit, Khaled A Hassan, Lucy B Kennedy, Gabriel Castilho S Barbosa
American Journal of Ophthalmology. 2026-09-01 - Role of EGFR-TKIs in Nonmetastatic Epidermal Growth Factor Receptor-Mutated Non-Small Cell Lung Cancer: A Comprehensive Review.Lukas Delasos, Khaled A Hassan
JCO Oncology Practice. 2026-07-01 - Pembrolizumab in Combination With Platinum-Based Chemotherapy in Patients With Recurrent EGFR and ALK Gene Altered Non-Small-Cell Lung Cancer (NSCLC).Shirish M Gadgeel, Misako Nagasaka, Karen Dziubek, Thomas Braun, Khaled Hassan
Clinical Lung Cancer. 2026-03-01
Journal Articles
- The EGFR T790M Mutation Is Acquired Through AICDA-Mediated Deamination of 5-Methylcytosine Following TKI Treatment in Lung CancerGregory P Kalemkerian, Khaled A Hassan, Clinical Cancer Research
Press Mentions
Nurturing Integrated Diagnostics in OncologyJanuary 20th, 2022
OncLive® Presents State of the Science Summit™ on Non-Small Cell Lung CancerSeptember 24th, 2019- Early Diagnosis and Significant Advances in Treatment Could Reduce High Lung Cancer Death Rate, Says Cleveland Clinic ExpertAugust 1st, 2023
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
